Cargando…

Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature

Peritoneal metastases from invasive lobular carcinoma (ILC) of breast are uncommon and usually related to poor prognosis due to difficulty of detection in clinical practice and drug resistance. Therefore, recognizing the entities of peritoneal metastases of ILC and the potential mechanism of drug re...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Hong-Fei, Zhang, Jun-Sheng, Zhang, Qiang-Zu, Zhu, Teng, Yang, Ci-Qiu, Zhang, Liu-Lu, Yang, Mei, Ji, Fei, Li, Jie-Qing, Cheng, Min-Yi, Niu, Gang, Wang, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531720/
https://www.ncbi.nlm.nih.gov/pubmed/34690920
http://dx.doi.org/10.3389/fendo.2021.659537
_version_ 1784586922900848640
author Gao, Hong-Fei
Zhang, Jun-Sheng
Zhang, Qiang-Zu
Zhu, Teng
Yang, Ci-Qiu
Zhang, Liu-Lu
Yang, Mei
Ji, Fei
Li, Jie-Qing
Cheng, Min-Yi
Niu, Gang
Wang, Kun
author_facet Gao, Hong-Fei
Zhang, Jun-Sheng
Zhang, Qiang-Zu
Zhu, Teng
Yang, Ci-Qiu
Zhang, Liu-Lu
Yang, Mei
Ji, Fei
Li, Jie-Qing
Cheng, Min-Yi
Niu, Gang
Wang, Kun
author_sort Gao, Hong-Fei
collection PubMed
description Peritoneal metastases from invasive lobular carcinoma (ILC) of breast are uncommon and usually related to poor prognosis due to difficulty of detection in clinical practice and drug resistance. Therefore, recognizing the entities of peritoneal metastases of ILC and the potential mechanism of drug resistance is of great significance for early detection and providing accurate management. We herein report a case of a 60-year-old female who presented with nausea and vomiting as the first manifestation after treated with abemaciclib (a CDK4/6 inhibitor) plus fulvestrant for 23 months due to bone metastasis of ILC. Exploratory laparotomy found multiple nodules in the peritoneum and omentum, and immunohistochemistry confirmed that the peritoneal metastatic lesions were consistent with ILC. Palliative therapy was initiated, but the patient died two months later due to disease progression with malignant ascites. Whole exome sequencing (WES) was used to detect the tumor samples and showed the peritoneal metastatic lesions had acquired ESR1 and PI3KCA mutations, potentially explaining the mechanism of endocrine therapy resistance. We argue that early diagnosis of peritoneal metastasis from breast cancer is crucial for prompt and adequate treatment and WES might be an effective supplementary technique for detection of potential gene mutations and providing accurate treatment for metastatic breast cancer patients.
format Online
Article
Text
id pubmed-8531720
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85317202021-10-23 Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature Gao, Hong-Fei Zhang, Jun-Sheng Zhang, Qiang-Zu Zhu, Teng Yang, Ci-Qiu Zhang, Liu-Lu Yang, Mei Ji, Fei Li, Jie-Qing Cheng, Min-Yi Niu, Gang Wang, Kun Front Endocrinol (Lausanne) Endocrinology Peritoneal metastases from invasive lobular carcinoma (ILC) of breast are uncommon and usually related to poor prognosis due to difficulty of detection in clinical practice and drug resistance. Therefore, recognizing the entities of peritoneal metastases of ILC and the potential mechanism of drug resistance is of great significance for early detection and providing accurate management. We herein report a case of a 60-year-old female who presented with nausea and vomiting as the first manifestation after treated with abemaciclib (a CDK4/6 inhibitor) plus fulvestrant for 23 months due to bone metastasis of ILC. Exploratory laparotomy found multiple nodules in the peritoneum and omentum, and immunohistochemistry confirmed that the peritoneal metastatic lesions were consistent with ILC. Palliative therapy was initiated, but the patient died two months later due to disease progression with malignant ascites. Whole exome sequencing (WES) was used to detect the tumor samples and showed the peritoneal metastatic lesions had acquired ESR1 and PI3KCA mutations, potentially explaining the mechanism of endocrine therapy resistance. We argue that early diagnosis of peritoneal metastasis from breast cancer is crucial for prompt and adequate treatment and WES might be an effective supplementary technique for detection of potential gene mutations and providing accurate treatment for metastatic breast cancer patients. Frontiers Media S.A. 2021-10-08 /pmc/articles/PMC8531720/ /pubmed/34690920 http://dx.doi.org/10.3389/fendo.2021.659537 Text en Copyright © 2021 Gao, Zhang, Zhang, Zhu, Yang, Zhang, Yang, Ji, Li, Cheng, Niu and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Gao, Hong-Fei
Zhang, Jun-Sheng
Zhang, Qiang-Zu
Zhu, Teng
Yang, Ci-Qiu
Zhang, Liu-Lu
Yang, Mei
Ji, Fei
Li, Jie-Qing
Cheng, Min-Yi
Niu, Gang
Wang, Kun
Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature
title Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature
title_full Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature
title_fullStr Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature
title_full_unstemmed Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature
title_short Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature
title_sort peritoneal metastasis after treated with abemaciclib plus fulvestrant for metastatic invasive lobular breast cancer: a case report and review of the literature
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531720/
https://www.ncbi.nlm.nih.gov/pubmed/34690920
http://dx.doi.org/10.3389/fendo.2021.659537
work_keys_str_mv AT gaohongfei peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature
AT zhangjunsheng peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature
AT zhangqiangzu peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature
AT zhuteng peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature
AT yangciqiu peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature
AT zhangliulu peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature
AT yangmei peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature
AT jifei peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature
AT lijieqing peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature
AT chengminyi peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature
AT niugang peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature
AT wangkun peritonealmetastasisaftertreatedwithabemaciclibplusfulvestrantformetastaticinvasivelobularbreastcanceracasereportandreviewoftheliterature